HLA
JUNO

Hamilton Lane Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Hamilton Lane Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-40,000
Closed -$1.52M – 65
2016
Q1 		$1.52M Buy
+40,000
New +$1.39M 0.73% 29
2015
Q3 		– Sell
-12,552
Closed -$669K – 69
2015
Q2 		$669K Buy
+12,552
New +$666K 0.25% 48

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hamilton Lane Advisors's JUNO Position: Q2 2016 in Review

Hamilton Lane Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2016, closing a stake of 40,000 shares — an estimated $1.52M sold.

Hamilton Lane Advisors first reported a position in JUNO in Q2 2015 and held it in 2 quarters. The position peaked at $1.52M in Q1 2016. 170 funds tracked by Wall St. Rank hold JUNO as of Q2 2016.

  • Hamilton Lane Advisors reported no remaining Juno Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Hamilton Lane Advisors sold 40,000 Juno Therapeutics, Inc. shares in Q2 2016, an estimated $1.52M.
  • Hamilton Lane Advisors first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
  • Hamilton Lane Advisors's Juno Therapeutics, Inc. position peaked at $1.52M in Q1 2016.
  • 170 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2016.

Based on Hamilton Lane Advisors's 13F filing for Q2 2016, filed 12 Jul 2016.